Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: Report of 3 cases

Dermatitis

Volumn 23, Issue 5, 2012, Pages 237-238

  Fabbrocini, Gabriella ^a   Panariello, Luigia ^a   Cacciapuoti, Sara ^a   Bianca, Dario ^a   Ayala, Fabio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; NAVELBINE; OXALIPLATIN; PANITUMUMAB; PEMETREXED;

ADULT; ALLERGIC RASH; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DRY SKIN; EYELASH; FEMALE; HAIR GROWTH; HUMAN; HYPERTRICHOSIS; LUNG METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PAPULAR RASH; PARONYCHIA; PRIORITY JOURNAL; RARE DISEASE; SKIN FISSURE; SKIN PRURITUS; SKIN TOXICITY; STOMACH CANCER; TREATMENT DURATION; TRICHOMEGALY; XEROSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; EXANTHEMA; EYELASHES; FEMALE; HAIR DISEASES; HUMANS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84871314646     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.1097/DER.0b013e31826e45d7     Document Type: Article

References (6)

1. Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer 2012;20(5):909-921.
2. Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011;50:129-146.
3. Alexandrescu DT, Kauffman CL, Dasanu CA. The cutaneous epidermal growth factor network: can it be translated clinically to stimulate hair growth? Dermatol Online J 2009;15:1.
4. LacoutureME, Anadkat MJ, Bensadoun RJ, et al. MASCC SkinToxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitorYassociated dermatologic toxicities. Support Care Cancer 2011;19:1079-1095.
5. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119.
6. Vergou T, Stratigos AJ, Karapanagiotou EM, et al. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 2010;63(2):e56-e58.